| scholarly article | Q13442814 |
| P2093 | author name string | Sung-Soo Park | |
| Soo-Youl Kim | |||
| Dae-Seok Kim | |||
| In-Hoo Kim | |||
| Jung-Mo Kim | |||
| P2860 | cites work | The NF-kappa B and I kappa B proteins: new discoveries and insights | Q24313579 |
| Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation | Q24316905 | ||
| A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB | Q24321775 | ||
| IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex | Q24530641 | ||
| Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex | Q28145172 | ||
| Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia | Q28582000 | ||
| Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis | Q29547538 | ||
| NF-kappaB: linking inflammation and immunity to cancer development and progression | Q29614597 | ||
| Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation | Q29614709 | ||
| The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta | Q29617188 | ||
| Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B | Q29618210 | ||
| Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies | Q33345317 | ||
| NF-kappa B as a therapeutic target in multiple myeloma | Q34521393 | ||
| Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis | Q34827307 | ||
| Proteasome: an emerging target for cancer therapy | Q36104401 | ||
| Transglutaminase 2 in inflammation | Q36486713 | ||
| IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy | Q40172372 | ||
| Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death | Q42441668 | ||
| A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. | Q45142085 | ||
| High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells | Q46198386 | ||
| Transglutaminases. | Q53905767 | ||
| Getting down to specifics | Q59087821 | ||
| P433 | issue | 46 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 34965-34972 | |
| P577 | publication date | 2006-09-20 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster | |
| P478 | volume | 281 |
| Q39162858 | Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. |
| Q33817561 | Bcr is a substrate for Transglutaminase 2 cross-linking activity |
| Q24304987 | Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking |
| Q28249358 | Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival |
| Q53140520 | Divergent results induced by different types of septic shock in transglutaminase 2 knockout mice. |
| Q35144563 | Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice |
| Q51653169 | Inter-molecular crosslinking activity is engendered by the dimeric form of transglutaminase 2. |
| Q35176934 | Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors. |
| Q47676785 | Pluripotency and a secretion mechanism of Drosophila Transglutaminase |
| Q28247511 | Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein |
| Q59794754 | Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition |
| Q92276539 | Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms as Potential Candidates |
| Q33490653 | The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition |
| Q36855739 | Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. |
| Q64899070 | Transglutaminase 2 Up-Regulation Is Associated with Inflammatory Response in PBMC from Healthy Subjects with Hypovitaminosis D. |
| Q38065965 | Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype |
| Q39798025 | Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer |
| Q53288102 | Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activation |
| Q28069852 | Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death |
| Q39017211 | Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models |
| Q39786229 | Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells |
| Q38713951 | Transglutaminase-catalyzed incorporation of polyamines masks the DNA-binding region of the transcription factor Relish |
| Q43954716 | Transglutaminase-catalyzed protein-protein cross-linking suppresses the activity of the NF-κB-like transcription factor relish |
| Q44811427 | Transglutaminases: future perspectives. |
Search more.